Medicortex Finland Oy

Medicortex Finland Oy Announces Issuance of a Patent in the United States

Share

TURKU, Finland. Medicortex Finland Oy, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering company’s diagnostic kit and innovative brain injury biomarker.

“This is our biggest achievement by now, we are extremely pleased with the development of the patent portfolio” said Dr. Harel Adrian, Chief Executive Officer of Medicortex. “This new issuance continues to expand the intellectual property portfolio covering methods of using certain biomarkers for detection of concussion. The issuance of this patent is another step in the development of a robust patent portfolio relating to new strategy to help identify and treat mild TBI” Dr. Harel continued with great pleasure.

Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid kit will satisfy the urgent need to improve the detection of brain injury in mild cases especially – which are known to be potentially morbid but difficult to diagnose with the contemporary means. The issued patent covers the core technology and method for detecting novel glycan-based biomarkers which are indicative of traumatic brain injury.

The issued US patent No. 10,739,335 “Prognostic and Diagnostic Glycan-Based Biomarkers of Brain Damage” is the second grant in the patent family where relative national patents were previously issued by the European Patent Office (EPO). Patenting of disease biomarkers and related diagnostics is becoming very tough in the USA, so the allowance of the current patent is a great achievement in that sense.

Medicortex’ patent portfolio encompasses diagnostics of TBI biomarkers as well as relative drug candidates developed by the company. The comprehensive patent coverage secures exclusivity to develop the products and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.

Keywords

Contacts

Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi

About Medicortex Finland Oy

Medicortex Finland Oy
Medicortex Finland Oy
Itäinen Pitkäkatu 4 B
20520 TURKU

http://www.medicortex.fi

Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence and severity of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologists Adrian Harel (PhD, MBA) in 2014, and the company is based in Turku, Finland.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Subscribe to releases from Medicortex Finland Oy

Subscribe to all the latest releases from Medicortex Finland Oy by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oy

Medicortex Finland Oy Announces the Advancement in Clinical Trial for Detection of Mild Traumatic Brain Injury in Children31.8.2020 15:43:39 EESTPress release

TURKU, Finland. Medicortex Finland Oy announces achievement of the halfway in the clinical trial for detection of mild traumatic brain injury (TBI) and concussion in children and adolescents. Company's third clinical trial is being conducted at Satasairaala hospital in Finland. About 50% of the target number of head injury patients and healthy controls have already been enrolled in the study which started in March this year.

Medicortex Finland Oy Announces the Progression of Clinical Trial for Detection of Mild Traumatic Brain Injury in Children9.6.2020 12:15:42 EESTPress release

TURKU, Finland. Medicortex Finland Oy announces the progression of clinical trial for detection of mild Traumatic Brain Injury (TBI) and concussion. Company’s third clinical trial is focusing on children and adolescents, and the recruitment of patients is taking place at Satasairaala hospital in Finland. The first patients with head injury and the first healthy controls have been enrolled in the study.

Medicortex Finland Oy:lle tutkimusrahoitusta Yhdysvaltain Puolustusministeriöltä3.7.2019 14:00:00 EESTTiedote

Turku, 03.07.2019. Medicortex Finland Oy:lle on myönnetty Yhdysvaltain puolustusministeriön 1,1 miljoonan dollarin tutkimusrahoitus. Rahoituksen avulla yhtiö jatkaa ProbTBITM -aivovammatestin kliinistä kehitystyötä. Tämä vahvasti kilpailtu rahoitus on samalla myös tunnustus Medicortexin teknologian ja tuotteen kyvylle vastata kasvavaan tarpeeseen määrittää tapaturmainen aivovamma tai aivotärähdys nopeasti ja luotettavasti.

Urheilulääketieteen asiantuntija Medicortex Finland Oy:n neuvonantajaksi10.12.2018 11:10:44 EETTiedote

Medicortex Finland Oy tiedottaa, että lääketieteen tohtori (LT) Markku Tuominen on liittynyt yhtiön Tieteellis-kliiniseen neuvottelukuntaan. Tuominen toimii Medisport Oy:n yrittäjänä ja ylilääkärinä. Lisäksi LT Tuominen toimii Kansainvälisen Jääkiekkoliiton lääketieteellisen valiokunnan jäsenenä sekä Suomen Jääkiekkoliiton lääkärinä. Tuominen on väitellyt Tampereen yliopiston Lääketieteen ja biotieteiden tiedekunnasta vuonna 2017 aiheena jääkiekkovammat MM- ja olympiaturnauksissa.